Why the study?
Do small-molecule modulators of platelet metabolism reduce platelet activation and thrombosis in preclinical models?
Population
ex vivo platelets and mouse models of thrombosis
Design
Preclinical
Authors
Loading...
Platelet metabolism modulation merits exploration as anti-thrombotic target; leaves open translation from murine models to clinical use.
Do small-molecule modulators of platelet metabolism reduce platelet activation and thrombosis in preclinical models?
Modulating platelet energy metabolism via aerobic glycolysis inhibitors like dichloroacetate and dehydroepiandrosterone represents a novel potential anti-thrombotic strategy.
Kulkarni et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: